<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Haemophilia A</title><meta name="description" content="Haemophilia A (or hemophilia A) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.[2][3][4] The medical management of individuals with hemophilia A primarily involves..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Hemophilia A, Classic hemophilia, Classical hemophilia, Factor VIII deficiency"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Haemophilia_A"/><meta property="og:title" content="Haemophilia A"/><meta property="og:description" content="Haemophilia A (or hemophilia A) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.[2][3][4] The medical management of individuals with hemophilia A primarily involves..."/><meta property="og:url" content="https://grokipedia.com/page/Haemophilia_A"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Haemophilia A"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.913Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Haemophilia A"/><meta name="twitter:description" content="Haemophilia A (or hemophilia A) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.[2][3][4] The medical management of individuals with hemophilia A primarily involves..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="4c8ab053a621078801cfe1d618617b7f-e6151e58e4c8e355-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=4c8ab053a621078801cfe1d618617b7f,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.3178564649744893,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#haemophilia-a" class="transition-opacity hover:opacity-100 opacity-50">Haemophilia A</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#signs-and-symptoms" class="transition-opacity hover:opacity-100 opacity-50">Signs and symptoms</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#complications" class="transition-opacity hover:opacity-100 opacity-50">Complications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#oral-manifestations" class="transition-opacity hover:opacity-100 opacity-50">Oral Manifestations</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#genetics" class="transition-opacity hover:opacity-100 opacity-50">Genetics</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis-of-haemophilia-a" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis of Haemophilia A</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#severity" class="transition-opacity hover:opacity-100 opacity-50">Severity</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#differential-diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Differential diagnosis</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment" class="transition-opacity hover:opacity-100 opacity-50">Treatment</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dental-considerations" class="transition-opacity hover:opacity-100 opacity-50">Dental considerations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#gene-therapy" class="transition-opacity hover:opacity-100 opacity-50">Gene therapy</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#monoclonal-antibodies" class="transition-opacity hover:opacity-100 opacity-50">Monoclonal antibodies</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prognosis" class="transition-opacity hover:opacity-100 opacity-50">Prognosis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#epidemiology" class="transition-opacity hover:opacity-100 opacity-50">Epidemiology</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="haemophilia-a" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Haemophilia A<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>





































<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Haemophilia A</strong> (or <strong>hemophilia A</strong>) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_71abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The medical management of individuals with hemophilia A primarily involves prophylactic replacement of factor VIII via intravenous infusion, non-factor prophylactic therapies such as emicizumab (administered subcutaneously), and emerging options like gene therapy (e.g., valoctocogene roxaparvovec, approved in 2023).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_31qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><br/>
<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_71qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h2 id="signs-and-symptoms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Signs and symptoms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Haemophilia A&#x27;s phenotype has a quite wide range of symptoms encompassing both internal and external bleeding episodes. Individuals with more severe haemophilia tend to experience more intense and frequent bleeding, whereas those with mild haemophilia typically exhibit milder symptoms unless subjected to surgical procedures or significant trauma. Those with moderate haemophilia may display variable symptoms, falling within the spectrum between severe and mild forms.</span>
<span class="mb-4 block break-words text-[1em] leading-7">One common early indicator of haemophilia is prolonged bleeding from venepuncture or heelpricks. These signs often prompt blood tests that confirm the presence of haemophilia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> In individuals, especially those with moderate or mild haemophilia, any form of trauma can trigger the first significant bleed. Haemophilia substantially elevates the risk of protracted bleeding from ordinary injuries, and in severe cases, bleeding can occur spontaneously without an apparent cause. Bleeding episodes can manifest anywhere in the body. Superficial bleeding resulting from abrasions or shallow lacerations may persist, with scabs easily breaking due to the deficiency of fibrin, potentially leading to re-bleeding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> While superficial bleeding poses challenges, more critical sites of bleeding include:<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_63abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Joints</li>
<li class="text-[1em]">Muscles</li>
<li class="text-[1em]">Digestive tract</li>
<li class="text-[1em]">Brain</li>
</ul>
<h3 id="complications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Complications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Recurrent bleeding into joints (hemarthrosis) can lead to chronic joint disease known as hemophilic arthropathy, which is the primary cause of morbidity and disability in people with severe haemophilia A.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_24qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Intracranial hemorrhage is a rare but life-threatening complication, particularly in neonates and young children, and is a leading cause of death.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">One therapeutic conundrum is the development of <em>inhibitor</em> antibodies against factor VIII due to frequent infusions. These develop as the body recognises the infused factor VIII as foreign, as the body does not produce its own <em>copy</em>. In these individuals, activated <span class="inline text-[1em] leading-7">factor VII</span>, a protein in the extrinsic pathway of the <span class="inline text-[1em] leading-7">coagulation cascade</span>, can be infused as a treatment for haemorrhage in individuals with haemophilia and antibodies against replacement factor VIII.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h3 id="oral-manifestations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Oral Manifestations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The oral manifestations are characterized by frequent bleeding of multiple sites, frequently seen as gingival and postextraction <span class="inline text-[1em] leading-7">haemorrhages</span>. The symptoms depend on the severity of haemophilia. In the case of severe haemophilia, patients may complain of multiple oral bleeding episodes throughout their life. Haemophilia patients are considered to be a special group of patients as routinely done procedures may be fatal in them. It was seen that almost 14% of all haemophilia patients and 30% of cases with a mild type of haemophilia have been diagnosed early following an episode of severe oral bleeding, of which the most common sites were the labial frenum and the tongue.</span>
<h2 id="genetics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Genetics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Haemophilia A is caused by pathogenic variants in the F8 gene, which encodes coagulation factor VIII and is located on the long arm of the X chromosome (Xq28).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Haemophilia A is inherited as an X-linked recessive trait. It occurs in males and in homozygous females (which is only possible in the daughters of a haemophilic male and a carrier or haemophiliac female<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup>). However, mild haemophilia A is known to occur in heterozygous females due to X-inactivation, so it is recommended that levels of factor VIII be measured in all known or potential carriers prior to surgery and in the event of clinically significant bleeding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">About 5-10% of people with haemophilia A are affected because they make a dysfunctional version of the factor VIII protein, while the remainder are affected because they produce factor VIII in insufficient amounts (quantitative deficiency).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Of those who have severe deficiency (defined as &lt;1% activity of factor VIII), 45-50% have the same mutation, an inversion within the factor VIII gene that results in total elimination of protein production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Since haemophilia A can be caused by a variety of different mutations, initial diagnosis and classification is done by measurement of protein activity rather than by genetic tests, though genetic tests are recommended for testing of family members once a known case of haemophilia is identified.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_38qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Approximately 30% of patients have no family history; their disease is presumably caused by new mutations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h1 id="diagnosis-of-haemophilia-a" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Diagnosis of Haemophilia A<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">The diagnosis of haemophilia A may be suspected as coagulation testing reveals an increased partial thromboplastin time (PTT) in the context of a normal prothrombin time (PT). Screening tests, including activated partial thromboplastin time (APTT or PTT) and prothrombin time (PT), are performed when hemophilia is suspected.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> However, the diagnosis is made in the presence of very low levels of factor VIII. A family history is frequently present, although not essential. Genetic testing is available to determine an individual&#x27;s risk of inheriting or passing on haemophilia. Genetic testing also enables carrier detection in females and prenatal diagnosis, often using techniques such as next-generation sequencing (NGS) for F8 gene mutations. Diagnosis of haemophilia A also includes a severity level, which can range from mild to severe based on the amount of active and functioning factor VIII detected in the blood. Factor VIII levels do not typically change throughout an individual&#x27;s lifetime. Severe haemophilia A is the most common severity, occurring in the majority of affected people. Individuals with mild haemophilia often experience few or no bleeding episodes except in the case of serious trauma (i.e. tooth extraction, or surgery).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="severity" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Severity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">There are numerous different mutations which can cause haemophilia A, due to differences in changes to the factor VIII gene (and the resulting protein). Individuals with haemophilia often have some level of active clotting factor. Individuals with less than 1% active factor are classified as having severe haemophilia, those with 1â€“5% active factor have moderate haemophilia, and those with mild haemophilia have between 5â€“40% of normal levels of active clotting factor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<h2 id="differential-diagnosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Differential diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Two of the most common differential diagnoses are haemophilia B which is a deficiency in Factor IX and von Willebrand Disease which is a deficiency in von Willebrand factor (needed for the proper functioning of Factor VIII<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup>); haemophilia C is also considered.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h1 id="treatment" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Most individuals with severe haemophilia require regular supplementation with <span class="inline text-[1em] leading-7">intravenous</span> <span class="inline text-[1em] leading-7">plasma</span> concentrate <span class="inline text-[1em] leading-7">factor VIII</span> or <span class="inline text-[1em] leading-7">efanesoctocog alfa</span>, a <span class="inline text-[1em] leading-7">von Willebrand factor</span> (VWF) independent, recombinant DNA-derived Factor VIII (FVIII) concentrate shown to prevent bleeding in children and adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> Treatment dosing and frequency of plasma concentrate Factor VIII may be variable and individually determined;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> dosing of efanesoctocog alfa shown effective is an IV injection of once-weekly 50 IU per kilogram of body weight.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In children, an easily accessible intravenous port<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> may have to be inserted to minimise frequent traumatic intravenous <span class="inline text-[1em] leading-7">cannulation</span>. These devices have made <span class="inline text-[1em] leading-7">prophylaxis</span> in haemophilia much easier for families because the problems of finding a vein for <span class="inline text-[1em] leading-7">infusion</span> several times a week are eliminated. However, there are risks involved with their use, the most worrisome being that of infection, studies differ but some show an infection rate that is high.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_adabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> These infections can usually be treated with <span class="inline text-[1em] leading-7">intravenous</span> antibiotics but sometimes the device must be removed,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_edabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> also, there are other studies that show a risk of clots forming at the tip of the catheter, rendering it useless. Some individuals with severe haemophilia, and most with moderate and mild haemophilia, treat only as needed without a regular prophylactic schedule.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Mild haemophiliacs often manage their condition with <span class="inline text-[1em] leading-7">desmopressin</span>, a drug which releases stored factor VIII from blood vessel walls.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Fitusiran</span> (Qfitlia) was approved for medical use in the United States in March 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<h3 id="dental-considerations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dental considerations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">If numbing is necessary for dental procedures, the nerve block (typically to the inferior alveolar nerve) should only be given after raising clotting factor levels by appropriate replacement therapy, as there is a risk of bleeding into the muscles along with potential airway compromise due to a haematoma in the retromolar or pterygoid space. The intraligamental technique or interosseous technique should be considered instead of the mandibular block. Articaine has been used as a buccal infiltration to anaesthetize the lower molar teeth. A lingual infiltration also requires appropriate factor replacement since the injection is into an area with a rich plexus of blood vessels and the needle is not adjacent to bone.</span>
<h3 id="gene-therapy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Gene therapy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In December 2017, it was reported that doctors had used a new form of <span class="inline text-[1em] leading-7">gene therapy</span> to treat haemophilia A.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> Valoctocogene roxaparvovec (Roctavian) was approved by the FDA in June 2023 for adults with severe haemophilia A (factor VIII activity less than 1 IU/dL) without preexisting factor VIII inhibitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Current approved gene therapies utilize adeno-associated virus (AAV) vectors; promising preclinical studies have explored lentiviral vectors (LV) as potential alternatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<h3 id="monoclonal-antibodies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Monoclonal antibodies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The <span class="inline text-[1em] leading-7">Monoclonal antibody</span> <span class="inline text-[1em] leading-7">emicizumab</span> (Hemlibra) was approved by the FDA in 2017.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="prognosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Prognosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Two Dutch studies followed hemophilia patients over several decades.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Earlier research from the 1970s to 1990s highlighted high rates of viral infections, such as HIV and hepatitis B and C, due to unscreened blood transfusions, which significantly impacted life expectancy. The 1992â€“2001 study reported a male life expectancy of 59 years overall, rising to 72 years excluding known viral infections, with 26% of deaths from AIDS and 22% from hepatitis C.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">However, these figures are outdated. Marked improvements in infection control, antiviral therapies, routine prophylaxis, and novel treatments (e.g., emicizumab, gene therapy) have transformed prognosis. A 2022 analysis of Dutch data from 2001â€“2018 found a median life expectancy of 77 years for males with hemophilia (73 years for severe hemophilia A), compared to 83 years in the general population, with a standardized mortality ratio of 1.4.<!-- --> In high-income countries, treated individuals with severe hemophilia A now have life expectancies within 5â€“10 years of the general male population (around 70â€“80 years as of 2025).</span>
<span class="mb-4 block break-words text-[1em] leading-7">Current leading causes of death include malignancies (26%), intracranial hemorrhage (14%), and cardiovascular disease, reflecting an aging population with comorbidities rather than infections.<!-- --> Access to care remains crucial, as disparities persist in low-resource settings.</span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup>
<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup>
<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<h2 id="epidemiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Epidemiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Haemophilia A occurs in approximately 1 in 5,000 male births worldwide,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> while haemophilia B occurs in about 1 in 25,000â€“30,000 male births.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Haemophilia A accounts for approximately 80â€“85% of all haemophilia cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The global prevalence of haemophilia A is estimated at around 12â€“17 cases per 100,000 males, though this varies by region due to underdiagnosis, particularly in low- and middle-income countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> According to the World Federation of Hemophilia, as of 2023, over 1 million people worldwide may be living with haemophilia (A and B combined), with many cases undiagnosed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> In the United States, about 20,000â€“30,000 males have haemophilia A.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Konkle, Barbara A.; Josephson, Neil C.; Nakaya Fletcher, Shelley (1993-01-01). Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora J.H.; Bird, Thomas D.; Fong, Chin-To; Mefford, Heather C. (eds.). <a href="https://www.ncbi.nlm.nih.gov/books/NBK1404/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Hemophilia A</em></a>. Seattle (WA): University of Washington, Seattle. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20301578" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20301578</a>.update 2014</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://medlineplus.gov/ency/article/000538.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hemophilia A: MedlinePlus Medical Encyclopedia&quot;</a>. <em><a href="http://www.nlm.nih.gov" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.nlm.nih.gov</a></em>. Retrieved 24 June 2016.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761083Orig1s000TOC.cfm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hemlibra (emicizumab-kxwh) Injection&quot;</a>. <em>accessdata.fda.gov</em>. 29 December 2017. Retrieved 29 March 2025.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://patient.info/doctor/haemophilia-a-factor-viii-deficiency" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Haemophilia A (Factor VIII Deficiency) information | Patient&quot;</a>. <em>Patient</em>. Retrieved 24 June 2016.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">World Health Organization</span> (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). <em>WHO Model Formulary 2008</em>. World Health Organization. pp. 259â€“60. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/10665%2F44053" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10665/44053</a>. <span class="inline text-[1em] leading-7">ISBN</span> 9789241547659.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nhlbi.nih.gov/health/bleeding-disorders/treatment" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;How Is Hemophilia Treated? - NHLBI, NIH&quot;</a>. <em><a href="http://www.nhlbi.nih.gov" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.nhlbi.nih.gov</a></em>. Retrieved 2016-07-08.</span></div></li><li id="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia</a></span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lissauer, Tom; Fanaroff, Avroy A.; Miall, Lawrence; Fanaroff, Jonathan (2015-06-10). <a href="https://books.google.com/books?id=hcfvCQAAQBAJ" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Neonatology at a Glance</em></a>. John Wiley &amp; Sons. p. 135. <span class="inline text-[1em] leading-7">ISBN</span> 9781118767429.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ma, Alice D.; Carrizosa, Daniel (2006-01-01). <a href="https://doi.org/10.1182%2Fasheducation-2006.1.432" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Acquired Factor VIII Inhibitors: Pathophysiology and Treatment&quot;</a>. <em>ASH Education Program Book</em>. <strong>2006</strong> (1): 432â€“437. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fasheducation-2006.1.432" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/asheducation-2006.1.432</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1520-4391" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1520-4391</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/17124095" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">17124095</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em>Sonu Acharya, Karishma Rathore, Upasana Mahapatra, Sashikant Sethi, Nikita Sahu (2018). &quot;An unusual oral manifestation of hemophilia in a child&quot;. Journal of International Oral Health. Retrieved 2019-12-20.</em></span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Nair, Preethi S.; Shetty, S.; Ghosh, Kanjaksha (2012-01-01). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385172" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;A homozygous female hemophilia A&quot;</a>. <em>Indian Journal of Human Genetics</em>. <strong>18</strong> (1): 134â€“136. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4103%2F0971-6866.96685" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4103/0971-6866.96685</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0971-6866" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0971-6866</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385172" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3385172</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22754241" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22754241</a>.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kliegman, Robert (2011). <em>Nelson textbook of pediatrics</em> (19th ed.). Philadelphia: Saunders. pp. 1700â€“1. <span class="inline text-[1em] leading-7">ISBN</span> 978-1-4377-0755-7.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bowen, D J (2002). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187139" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Haemophilia A and haemophilia B: molecular insights&quot;</a>. <em>Molecular Pathology</em>. <strong>55</strong> (1): 1â€“18. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1136%2Fmp.55.1.1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1136/mp.55.1.1</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187139" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1187139</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11836440" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11836440</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://omim.org/entry/306700" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;OMIM Entry - # 306700 - HEMOPHILIA A; HEMA&quot;</a>. <em>omim.org</em>. Retrieved 2016-07-08.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em><a href="https://emedicine.medscape.com/article/210104-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Hemophilia A</a></em> at <span class="inline text-[1em] leading-7">eMedicine</span></span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://patient.info/doctor/von-willebrands-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Von Willebrand&#x27;s Disease. About Von Willebrand&#x27;s Disease | Patient&quot;</a>. <em>Patient</em>. Retrieved 2016-07-08.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">von Drygalski, Annette; Chowdary, Pratima; Kulkarni, Roshni; Susen, Sophie; Konkle, Barbara A.; Oldenburg, Johannes; Matino, Davide; Klamroth, Robert; Weyand, Angela C.; Jimenez-Yuste, Victor; Nogami, Keiji; Poloskey, Stacey; Winding, Bent; Willemze, Annemieke; Knobe, Karin (2023-01-26). <a href="http://www.nejm.org/doi/10.1056/NEJMoa2209226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A&quot;</a>. <em>New England Journal of Medicine</em>. <strong>388</strong> (4): 310â€“318. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1056%2FNEJMoa2209226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1056/NEJMoa2209226</a>. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/2078.1%2F274138" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2078.1/274138</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0028-4793" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0028-4793</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/36720133" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">36720133</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Malec, Lynn; Peyvandi, Flora; Chan, Anthony K.C.; KÃ¶nigs, Christoph; Zulfikar, Bulent; Yuan, Huixing; Simpson, Mindy; Ãlvarez RomÃ¡n, Maria Teresa; Carcao, Manuel; Staber, Janice M.; Dunn, Amy L.; Chou, Sheng-Chieh; d&#x27;Oiron, Roseline; Albisetti, Manuela; Demissie, Marek (2024-07-18). <a href="http://www.nejm.org/doi/10.1056/NEJMoa2312611" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A&quot;</a>. <em>New England Journal of Medicine</em>. <strong>391</strong> (3): 235â€“246. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1056%2FNEJMoa2312611" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1056/NEJMoa2312611</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0028-4793" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0028-4793</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/39018533" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">39018533</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ma, Alice D.; Roberts, Harold R.; Escobar, Miguel A. (2012-10-03). <a href="https://books.google.com/books?id=JeCD7cUVeTEC" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Hemophilia and Hemostasis: A Case-Based Approach to Management</em></a>. John Wiley &amp; Sons. <span class="inline text-[1em] leading-7">ISBN</span> 9781118439302.Google books no page</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Santagostino, Elena; Mancuso, Maria Elisa (2008-09-01). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652218" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Barriers to primary prophylaxis in haemophilic children: the issue of the venous access&quot;</a>. <em>Blood Transfusion</em>. <strong>6</strong> (Suppl 2): s12 â€“ s16. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2450%2F2008.0031-08" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2450/2008.0031-08</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1723-2007" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1723-2007</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652218" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2652218</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19105504" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19105504</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Guidelines for the Prevention of Intravascular Catheter-Related Infections&quot;</a>. <em><a href="http://www.cdc.gov" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.cdc.gov</a></em>. Retrieved 8 July 2016.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors&quot;</a>. <em>U.S. Food and Drug Administration</em>. 28 March 2025. Retrieved 29 March 2025.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.news.sanofi.us/2025-03-28-Qfitlia-approved-as-the-first-therapy-in-the-US-to-treat-hemophilia-A-or-B-with-or-without-inhibitors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors&quot;</a>. <em>Sanofi</em> (Press release). 28 March 2025. Retrieved 29 March 2025.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em>Andrew Brewer, Maria Elvira Correa (May 2006). &quot;Guildelines for Dental Treatment of Patients with Inherited Bleeding Disorders&quot; (PDF). Treatment of Hemophilia.<strong>40</strong> : 9 â€“ via World Federation of Hemophilia (WFH).</em></span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bartshealth.nhs.uk/news/groundbreaking-gene-therapy-trial-set-to-cure-haemophilia-a-2529" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Groundbreaking gene therapy trial set to cure haemophilia A&quot;</a>. <em>Barts Health NHS Trust</em>. 14 December 2017. Retrieved 14 December 2017.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bbc.com/news/health-42337396" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Haemophilia A trial results &#x27;mind-blowing&#x27;&quot;</a>. <em>BBC</em>. 14 December 2017. Retrieved 14 December 2017.</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rangarajan, Savita; Walsh, Liron; Lester, Will; Perry, David; Madan, Bella; Laffan, Michael; Yu, Hua; Vettermann, Christian; Pierce, Glenn F.; Wong, Wing Y.; Pasi, K. John (16 December 2017). <a href="http://qmro.qmul.ac.uk/xmlui/handle/123456789/31880" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;AAV5â€“Factor VIII Gene Transfer in Severe Hemophilia A&quot;</a>. <em>New England Journal of Medicine</em>. <strong>377</strong> (26): 2519â€“2530. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1056%2FNEJMoa1708483" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1056/NEJMoa1708483</a>. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/10044%2F1%2F57163" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10044/1/57163</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29224506" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29224506</a>.</span></div></li><li id="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products</a></span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Marchesini, Emanuela; Morfini, Massimo; Valentino, Leonard (2021-06-15). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214539" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Recent Advances in the Treatment of Hemophilia: A Review&quot;</a>. <em>Biologics: Targets and Therapy</em>. <strong>15</strong> : 221â€“235. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2147%2FBTT.S252580" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2147/BTT.S252580</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214539" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8214539</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34163136" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34163136</a>.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Milani, Michela; Canepari, Cesare; Assanelli, Simone; Merlin, Simone; Borroni, Ester; Starinieri, Francesco; Biffi, Mauro; Russo, Fabio; Fabiano, Anna; Zambroni, DesirÃ¨e; Annoni, Andrea; Naldini, Luigi; Follenzi, Antonia; Cantore, Alessio (2024-04-29). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178766" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice&quot;</a>. <em>EMBO Molecular Medicine</em>. <strong>16</strong> (6): 1427â€“1450. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fs44321-024-00072-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/s44321-024-00072-8</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1757-4684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1757-4684</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178766" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11178766</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/38684862" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">38684862</a>.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Triemstra, Mattanja (1995-12-01). &quot;Mortality in Patients with Hemophilia: Changes in a Dutch Population from 1986 to 1992 and 1973 to 1986&quot;. <em>Annals of Internal Medicine</em>. <strong>123</strong> (11): 823â€“7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.7326%2F0003-4819-123-11-199512010-00002" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.7326/0003-4819-123-11-199512010-00002</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0003-4819" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0003-4819</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7486463" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7486463</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:22008880" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22008880</a>.</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Plug, I.; Van Der Bom, J. G.; Peters, M.; Mauser-Bunschoten, E. P.; De Goede-Bolder, A.; Heijnen, L.; Smit, C.; Willemse, J.; Rosendaal, F. R. (2006-03-01). &quot;Mortality and causes of death in patients with hemophilia, 1992â€“2001: a prospective cohort study1&quot;. <em>Journal of Thrombosis and Haemostasis</em>. <strong>4</strong> (3): 510â€“516. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fj.1538-7836.2006.01808.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/j.1538-7836.2006.01808.x</a>. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/1887%2F5021" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1887/5021</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1538-7836" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1538-7836</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16460432" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16460432</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:13651790" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">13651790</a>.</span></div></li><li id="https://doi.org/10.1111/jth.15182" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1111/jth.15182" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1111/jth.15182</a></span></div></li><li id="https://hemophilianewstoday.com/hemophilia-prognosis-life-expectancy/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://hemophilianewstoday.com/hemophilia-prognosis-life-expectancy/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://hemophilianewstoday.com/hemophilia-prognosis-life-expectancy/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1538783622021274" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1538783622021274" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1538783622021274</a></span></div></li><li id="https://www.cdc.gov/hemophilia/data-research/index.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/hemophilia/data-research/index.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/hemophilia/data-research/index.html</a></span></div></li><li id="https://wfh.org/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://wfh.org/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://wfh.org/</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Haemophilia_A" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm" id="_R_" async=""></script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Haemophilia_A\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Haemophilia_A\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Haemophilia_A\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T36a5,"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"# Haemophilia A\n\n| **Attribute** | **Details** |\n|---------------|-------------|\n| Other names | Hemophilia A |\n| Specialty | Haematology |\n| Symptoms | Prolonged bleeding from common injuries[1] |\n| Causes | Factor VIII deficiency[2] |\n| Diagnostic method | Activated partial thromboplastin time (aPTT),[2] coagulation screen, genetic testing |\n| Prevention | Hepatitis B vaccine should be considered[2] |\n| Treatment | Factor VIII replacement, bypassing agents for inhibitors, emicizumab[30] |\n\n**Haemophilia A** (or **hemophilia A**) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.[2][3][4]\n\nThe medical management of individuals with hemophilia A primarily involves prophylactic replacement of factor VIII via intravenous infusion, non-factor prophylactic therapies such as emicizumab (administered subcutaneously), and emerging options like gene therapy (e.g., valoctocogene roxaparvovec, approved in 2023).[2][6][30]  \n[](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia)\n# Haemophilia A\n\n## Signs and symptoms\n\nHaemophilia A's phenotype has a quite wide range of symptoms encompassing both internal and external bleeding episodes. Individuals with more severe haemophilia tend to experience more intense and frequent bleeding, whereas those with mild haemophilia typically exhibit milder symptoms unless subjected to surgical procedures or significant trauma. Those with moderate haemophilia may display variable symptoms, falling within the spectrum between severe and mild forms. \n\nOne common early indicator of haemophilia is prolonged bleeding from venepuncture or heelpricks. These signs often prompt blood tests that confirm the presence of haemophilia.[5] In individuals, especially those with moderate or mild haemophilia, any form of trauma can trigger the first significant bleed. Haemophilia substantially elevates the risk of protracted bleeding from ordinary injuries, and in severe cases, bleeding can occur spontaneously without an apparent cause. Bleeding episodes can manifest anywhere in the body. Superficial bleeding resulting from abrasions or shallow lacerations may persist, with scabs easily breaking due to the deficiency of fibrin, potentially leading to re-bleeding.[1] While superficial bleeding poses challenges, more critical sites of bleeding include:[6]\n\n* Joints\n* Muscles\n* Digestive tract\n* Brain\n\n### Complications\n\nRecurrent bleeding into joints (hemarthrosis) can lead to chronic joint disease known as hemophilic arthropathy, which is the primary cause of morbidity and disability in people with severe haemophilia A.[1] Intracranial hemorrhage is a rare but life-threatening complication, particularly in neonates and young children, and is a leading cause of death.[1]\n\nOne therapeutic conundrum is the development of *inhibitor* antibodies against factor VIII due to frequent infusions. These develop as the body recognises the infused factor VIII as foreign, as the body does not produce its own *copy*. In these individuals, activated [factor VII](Factor_VII \"Factor VII\"), a protein in the extrinsic pathway of the [coagulation cascade](Coagulation_cascade \"Coagulation cascade\"), can be infused as a treatment for haemorrhage in individuals with haemophilia and antibodies against replacement factor VIII.[1][7]\n\n### Oral Manifestations\n\nThe oral manifestations are characterized by frequent bleeding of multiple sites, frequently seen as gingival and postextraction [haemorrhages](Bleeding \"Bleeding\"). The symptoms depend on the severity of haemophilia. In the case of severe haemophilia, patients may complain of multiple oral bleeding episodes throughout their life. Haemophilia patients are considered to be a special group of patients as routinely done procedures may be fatal in them. It was seen that almost 14% of all haemophilia patients and 30% of cases with a mild type of haemophilia have been diagnosed early following an episode of severe oral bleeding, of which the most common sites were the labial frenum and the tongue.[8]\n## Genetics\n\nHaemophilia A is caused by pathogenic variants in the F8 gene, which encodes coagulation factor VIII and is located on the long arm of the X chromosome (Xq28).[1]\n\nHaemophilia A is inherited as an X-linked recessive trait. It occurs in males and in homozygous females (which is only possible in the daughters of a haemophilic male and a carrier or haemophiliac female[9]). However, mild haemophilia A is known to occur in heterozygous females due to X-inactivation, so it is recommended that levels of factor VIII be measured in all known or potential carriers prior to surgery and in the event of clinically significant bleeding.[1][10]\n\nAbout 5-10% of people with haemophilia A are affected because they make a dysfunctional version of the factor VIII protein, while the remainder are affected because they produce factor VIII in insufficient amounts (quantitative deficiency).[10] Of those who have severe deficiency (defined as \u003c1% activity of factor VIII), 45-50% have the same mutation, an inversion within the factor VIII gene that results in total elimination of protein production.[10]\n\nSince haemophilia A can be caused by a variety of different mutations, initial diagnosis and classification is done by measurement of protein activity rather than by genetic tests, though genetic tests are recommended for testing of family members once a known case of haemophilia is identified.[1][10] Approximately 30% of patients have no family history; their disease is presumably caused by new mutations.[11]\n# Diagnosis of Haemophilia A\n\nThe diagnosis of haemophilia A may be suspected as coagulation testing reveals an increased partial thromboplastin time (PTT) in the context of a normal prothrombin time (PT). Screening tests, including activated partial thromboplastin time (APTT or PTT) and prothrombin time (PT), are performed when hemophilia is suspected.[12] However, the diagnosis is made in the presence of very low levels of factor VIII. A family history is frequently present, although not essential. Genetic testing is available to determine an individual's risk of inheriting or passing on haemophilia. Genetic testing also enables carrier detection in females and prenatal diagnosis, often using techniques such as next-generation sequencing (NGS) for F8 gene mutations. Diagnosis of haemophilia A also includes a severity level, which can range from mild to severe based on the amount of active and functioning factor VIII detected in the blood. Factor VIII levels do not typically change throughout an individual's lifetime. Severe haemophilia A is the most common severity, occurring in the majority of affected people. Individuals with mild haemophilia often experience few or no bleeding episodes except in the case of serious trauma (i.e. tooth extraction, or surgery).[1]\n\n## Severity\n\nThere are numerous different mutations which can cause haemophilia A, due to differences in changes to the factor VIII gene (and the resulting protein). Individuals with haemophilia often have some level of active clotting factor. Individuals with less than 1% active factor are classified as having severe haemophilia, those with 1â€“5% active factor have moderate haemophilia, and those with mild haemophilia have between 5â€“40% of normal levels of active clotting factor.[13]\n\n## Differential diagnosis\n\nTwo of the most common differential diagnoses are haemophilia B which is a deficiency in Factor IX and von Willebrand Disease which is a deficiency in von Willebrand factor (needed for the proper functioning of Factor VIII[14]); haemophilia C is also considered.[3]\n# Treatment\n\nMost individuals with severe haemophilia require regular supplementation with [intravenous](Intravenous \"Intravenous\") [plasma](Blood_plasma \"Blood plasma\") concentrate [factor VIII](Factor_VIII_(medication) \"Factor VIII \\(medication\\)\") or [efanesoctocog alfa](Efanesoctocog_alfa \"Efanesoctocog alfa\"), a [von Willebrand factor](Von_Willebrand_factor \"Von Willebrand factor\") (VWF) independent, recombinant DNA-derived Factor VIII (FVIII) concentrate shown to prevent bleeding in children and adults.[15][16] Treatment dosing and frequency of plasma concentrate Factor VIII may be variable and individually determined;[6] dosing of efanesoctocog alfa shown effective is an IV injection of once-weekly 50 IU per kilogram of body weight. \n\nIn children, an easily accessible intravenous port[17] may have to be inserted to minimise frequent traumatic intravenous [cannulation](Cannulation \"Cannulation\"). These devices have made [prophylaxis](Prophylaxis \"Prophylaxis\") in haemophilia much easier for families because the problems of finding a vein for [infusion](Infusion \"Infusion\") several times a week are eliminated. However, there are risks involved with their use, the most worrisome being that of infection, studies differ but some show an infection rate that is high.[18] These infections can usually be treated with [intravenous](Intravenous \"Intravenous\") antibiotics but sometimes the device must be removed,[19] also, there are other studies that show a risk of clots forming at the tip of the catheter, rendering it useless. Some individuals with severe haemophilia, and most with moderate and mild haemophilia, treat only as needed without a regular prophylactic schedule.[1] Mild haemophiliacs often manage their condition with [desmopressin](Desmopressin \"Desmopressin\"), a drug which releases stored factor VIII from blood vessel walls.[1]\n\n[Fitusiran](Fitusiran \"Fitusiran\") (Qfitlia) was approved for medical use in the United States in March 2025.[22][23]\n\n### Dental considerations\n\nIf numbing is necessary for dental procedures, the nerve block (typically to the inferior alveolar nerve) should only be given after raising clotting factor levels by appropriate replacement therapy, as there is a risk of bleeding into the muscles along with potential airway compromise due to a haematoma in the retromolar or pterygoid space. The intraligamental technique or interosseous technique should be considered instead of the mandibular block. Articaine has been used as a buccal infiltration to anaesthetize the lower molar teeth. A lingual infiltration also requires appropriate factor replacement since the injection is into an area with a rich plexus of blood vessels and the needle is not adjacent to bone.[24]\n\n### Gene therapy\n\nIn December 2017, it was reported that doctors had used a new form of [gene therapy](Gene_therapy \"Gene therapy\") to treat haemophilia A.[25][26][27] Valoctocogene roxaparvovec (Roctavian) was approved by the FDA in June 2023 for adults with severe haemophilia A (factor VIII activity less than 1 IU/dL) without preexisting factor VIII inhibitors.[](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products) Current approved gene therapies utilize adeno-associated virus (AAV) vectors; promising preclinical studies have explored lentiviral vectors (LV) as potential alternatives.[28][29]\n\n### Monoclonal antibodies\n\nThe [Monoclonal antibody](Monoclonal_antibody \"Monoclonal antibody\") [emicizumab](Emicizumab \"Emicizumab\") (Hemlibra) was approved by the FDA in 2017.[30]\n## Prognosis\n\nTwo Dutch studies followed hemophilia patients over several decades.[33][34] Earlier research from the 1970s to 1990s highlighted high rates of viral infections, such as HIV and hepatitis B and C, due to unscreened blood transfusions, which significantly impacted life expectancy. The 1992â€“2001 study reported a male life expectancy of 59 years overall, rising to 72 years excluding known viral infections, with 26% of deaths from AIDS and 22% from hepatitis C.[34]\n\nHowever, these figures are outdated. Marked improvements in infection control, antiviral therapies, routine prophylaxis, and novel treatments (e.g., emicizumab, gene therapy) have transformed prognosis. A 2022 analysis of Dutch data from 2001â€“2018 found a median life expectancy of 77 years for males with hemophilia (73 years for severe hemophilia A), compared to 83 years in the general population, with a standardized mortality ratio of 1.4.[35] In high-income countries, treated individuals with severe hemophilia A now have life expectancies within 5â€“10 years of the general male population (around 70â€“80 years as of 2025).[36]\n\nCurrent leading causes of death include malignancies (26%), intracranial hemorrhage (14%), and cardiovascular disease, reflecting an aging population with comorbidities rather than infections.[35][37] Access to care remains crucial, as disparities persist in low-resource settings.\n\n[](https://doi.org/10.1111/jth.15182)\n[](https://hemophilianewstoday.com/hemophilia-prognosis-life-expectancy/)\n[](https://www.sciencedirect.com/science/article/pii/S1538783622021274)\n## Epidemiology\n\nHaemophilia A occurs in approximately 1 in 5,000 male births worldwide,[10] while haemophilia B occurs in about 1 in 25,000â€“30,000 male births.[10] Haemophilia A accounts for approximately 80â€“85% of all haemophilia cases.[22]\n\nThe global prevalence of haemophilia A is estimated at around 12â€“17 cases per 100,000 males, though this varies by region due to underdiagnosis, particularly in low- and middle-income countries.[](https://www.cdc.gov/hemophilia/data-research/index.html) According to the World Federation of Hemophilia, as of 2023, over 1 million people worldwide may be living with haemophilia (A and B combined), with many cases undiagnosed.[](https://wfh.org/) In the United States, about 20,000â€“30,000 males have haemophilia A.[](https://www.cdc.gov/hemophilia/data-research/index.html)"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761887609735,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Konkle, Barbara A.; Josephson, Neil C.; Nakaya Fletcher, Shelley (1993-01-01). Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora J.H.; Bird, Thomas D.; Fong, Chin-To; Mefford, Heather C. (eds.). [_Hemophilia A_](https://www.ncbi.nlm.nih.gov/books/NBK1404/). Seattle (WA): University of Washington, Seattle. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20301578](https://pubmed.ncbi.nlm.nih.gov/20301578).update 2014\",\"description\":\"1. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Konkle, Barbara A.; Josephson, Neil C.; Nakaya Fletcher, Shelley (1993-01-01). Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora J.H.; Bird, Thomas D.; Fong, Chin-To; Mefford, Heather C. (eds.). [_Hemophilia A_](https://www.ncbi.nlm.nih.gov/books/NBK1404/). Seattle (WA): University of Washington, Seattle. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20301578](https://pubmed.ncbi.nlm.nih.gov/20301578).update 2014\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK1404/\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ [\\\"Hemophilia A: MedlinePlus Medical Encyclopedia\\\"](https://medlineplus.gov/ency/article/000538.htm). _www.nlm.nih.gov_. Retrieved 24 June 2016.\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ _**d**_ [\\\"Hemophilia A: MedlinePlus Medical Encyclopedia\\\"](https://medlineplus.gov/ency/article/000538.htm). _www.nlm.nih.gov_. Retrieved 24 June 2016.\",\"url\":\"https://medlineplus.gov/ency/article/000538.htm\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"_**a**_ _**b**_ [\\\"Haemophilia A (Factor VIII Deficiency) information | Patient\\\"](https://patient.info/doctor/haemophilia-a-factor-viii-deficiency). _Patient_. Retrieved 24 June 2016.\",\"description\":\"3. ^ _**a**_ _**b**_ [\\\"Haemophilia A (Factor VIII Deficiency) information | Patient\\\"](https://patient.info/doctor/haemophilia-a-factor-viii-deficiency). _Patient_. Retrieved 24 June 2016.\",\"url\":\"https://patient.info/doctor/haemophilia-a-factor-viii-deficiency\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** [World Health Organization](World_Health_Organization \\\"World Health Organization\\\") (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). _WHO Model Formulary 2008_. World Health Organization. pp. 259â€“60\\\\. [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10665/44053](https://hdl.handle.net/10665%2F44053). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9789241547659.\",\"description\":\"4. **^** [World Health Organization](World_Health_Organization \\\"World Health Organization\\\") (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). _WHO Model Formulary 2008_. World Health Organization. pp. 259â€“60\\\\. [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10665/44053](https://hdl.handle.net/10665%2F44053). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9789241547659.\",\"url\":\"World_Health_Organization \\\"World Health Organization\\\"\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** Lissauer, Tom; Fanaroff, Avroy A.; Miall, Lawrence; Fanaroff, Jonathan (2015-06-10). [_Neonatology at a Glance_](https://books.google.com/books?id=hcfvCQAAQBAJ). John Wiley \u0026 Sons. p. 135\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781118767429.\",\"description\":\"5. **^** Lissauer, Tom; Fanaroff, Avroy A.; Miall, Lawrence; Fanaroff, Jonathan (2015-06-10). [_Neonatology at a Glance_](https://books.google.com/books?id=hcfvCQAAQBAJ). John Wiley \u0026 Sons. p. 135\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781118767429.\",\"url\":\"https://books.google.com/books?id=hcfvCQAAQBAJ\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"_**a**_ _**b**_ [\\\"How Is Hemophilia Treated? - NHLBI, NIH\\\"](https://www.nhlbi.nih.gov/health/bleeding-disorders/treatment). _www.nhlbi.nih.gov_. Retrieved 2016-07-08.\",\"description\":\"6. ^ _**a**_ _**b**_ [\\\"How Is Hemophilia Treated? - NHLBI, NIH\\\"](https://www.nhlbi.nih.gov/health/bleeding-disorders/treatment). _www.nhlbi.nih.gov_. Retrieved 2016-07-08.\",\"url\":\"https://www.nhlbi.nih.gov/health/bleeding-disorders/treatment\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Ma, Alice D.; Carrizosa, Daniel (2006-01-01). [\\\"Acquired Factor VIII Inhibitors: Pathophysiology and Treatment\\\"](https://doi.org/10.1182%2Fasheducation-2006.1.432). _ASH Education Program Book_. **2006** (1): 432â€“437\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/asheducation-2006.1.432](https://doi.org/10.1182%2Fasheducation-2006.1.432). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1520-4391](https://search.worldcat.org/issn/1520-4391). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17124095](https://pubmed.ncbi.nlm.nih.gov/17124095).\",\"description\":\"7. **^** Ma, Alice D.; Carrizosa, Daniel (2006-01-01). [\\\"Acquired Factor VIII Inhibitors: Pathophysiology and Treatment\\\"](https://doi.org/10.1182%2Fasheducation-2006.1.432). _ASH Education Program Book_. **2006** (1): 432â€“437\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/asheducation-2006.1.432](https://doi.org/10.1182%2Fasheducation-2006.1.432). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1520-4391](https://search.worldcat.org/issn/1520-4391). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17124095](https://pubmed.ncbi.nlm.nih.gov/17124095).\",\"url\":\"https://doi.org/10.1182%2Fasheducation-2006.1.432\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** _Sonu Acharya, Karishma Rathore, Upasana Mahapatra, Sashikant Sethi, Nikita Sahu (2018). \\\"An unusual oral manifestation of hemophilia in a child\\\". Journal of International Oral Health. Retrieved 2019-12-20._\",\"description\":\"8. **^** _Sonu Acharya, Karishma Rathore, Upasana Mahapatra, Sashikant Sethi, Nikita Sahu (2018). \\\"An unusual oral manifestation of hemophilia in a child\\\". Journal of International Oral Health. Retrieved 2019-12-20._\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** Nair, Preethi S.; Shetty, S.; Ghosh, Kanjaksha (2012-01-01). [\\\"A homozygous female hemophilia A\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385172). _Indian Journal of Human Genetics_. **18** (1): 134â€“136\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4103/0971-6866.96685](https://doi.org/10.4103%2F0971-6866.96685). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0971-6866](https://search.worldcat.org/issn/0971-6866). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3385172](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385172). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22754241](https://pubmed.ncbi.nlm.nih.gov/22754241).\",\"description\":\"9. **^** Nair, Preethi S.; Shetty, S.; Ghosh, Kanjaksha (2012-01-01). [\\\"A homozygous female hemophilia A\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385172). _Indian Journal of Human Genetics_. **18** (1): 134â€“136\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4103/0971-6866.96685](https://doi.org/10.4103%2F0971-6866.96685). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0971-6866](https://search.worldcat.org/issn/0971-6866). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3385172](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385172). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22754241](https://pubmed.ncbi.nlm.nih.gov/22754241).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385172\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ Kliegman, Robert (2011). _Nelson textbook of pediatrics_ (19th ed.). Philadelphia: Saunders. pp. 1700â€“1\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-4377-0755-7.\",\"description\":\"10. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ Kliegman, Robert (2011). _Nelson textbook of pediatrics_ (19th ed.). Philadelphia: Saunders. pp. 1700â€“1\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-4377-0755-7.\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Bowen, D J (2002). [\\\"Haemophilia A and haemophilia B: molecular insights\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187139). _Molecular Pathology_. **55** (1): 1â€“18\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/mp.55.1.1](https://doi.org/10.1136%2Fmp.55.1.1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1187139](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187139). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11836440](https://pubmed.ncbi.nlm.nih.gov/11836440).\",\"description\":\"11. **^** Bowen, D J (2002). [\\\"Haemophilia A and haemophilia B: molecular insights\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187139). _Molecular Pathology_. **55** (1): 1â€“18\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/mp.55.1.1](https://doi.org/10.1136%2Fmp.55.1.1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1187139](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187139). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11836440](https://pubmed.ncbi.nlm.nih.gov/11836440).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187139\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** [\\\"OMIM Entry - # 306700 - HEMOPHILIA A; HEMA\\\"](http://omim.org/entry/306700). _omim.org_. Retrieved 2016-07-08.\",\"description\":\"12. **^** [\\\"OMIM Entry - # 306700 - HEMOPHILIA A; HEMA\\\"](http://omim.org/entry/306700). _omim.org_. Retrieved 2016-07-08.\",\"url\":\"http://omim.org/entry/306700\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** _[Hemophilia A](https://emedicine.medscape.com/article/210104-overview)_ at [eMedicine](EMedicine \\\"EMedicine\\\")\",\"description\":\"13. **^** _[Hemophilia A](https://emedicine.medscape.com/article/210104-overview)_ at [eMedicine](EMedicine \\\"EMedicine\\\")\",\"url\":\"https://emedicine.medscape.com/article/210104-overview\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** [\\\"Von Willebrand's Disease. About Von Willebrand's Disease | Patient\\\"](https://patient.info/doctor/von-willebrands-disease). _Patient_. Retrieved 2016-07-08.\",\"description\":\"14. **^** [\\\"Von Willebrand's Disease. About Von Willebrand's Disease | Patient\\\"](https://patient.info/doctor/von-willebrands-disease). _Patient_. Retrieved 2016-07-08.\",\"url\":\"https://patient.info/doctor/von-willebrands-disease\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** von Drygalski, Annette; Chowdary, Pratima; Kulkarni, Roshni; Susen, Sophie; Konkle, Barbara A.; Oldenburg, Johannes; Matino, Davide; Klamroth, Robert; Weyand, Angela C.; Jimenez-Yuste, Victor; Nogami, Keiji; Poloskey, Stacey; Winding, Bent; Willemze, Annemieke; Knobe, Karin (2023-01-26). [\\\"Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A\\\"](http://www.nejm.org/doi/10.1056/NEJMoa2209226). _New England Journal of Medicine_. **388** (4): 310â€“318\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa2209226](https://doi.org/10.1056%2FNEJMoa2209226). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[2078.1/274138](https://hdl.handle.net/2078.1%2F274138). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36720133](https://pubmed.ncbi.nlm.nih.gov/36720133).\",\"description\":\"15. **^** von Drygalski, Annette; Chowdary, Pratima; Kulkarni, Roshni; Susen, Sophie; Konkle, Barbara A.; Oldenburg, Johannes; Matino, Davide; Klamroth, Robert; Weyand, Angela C.; Jimenez-Yuste, Victor; Nogami, Keiji; Poloskey, Stacey; Winding, Bent; Willemze, Annemieke; Knobe, Karin (2023-01-26). [\\\"Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A\\\"](http://www.nejm.org/doi/10.1056/NEJMoa2209226). _New England Journal of Medicine_. **388** (4): 310â€“318\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa2209226](https://doi.org/10.1056%2FNEJMoa2209226). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[2078.1/274138](https://hdl.handle.net/2078.1%2F274138). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36720133](https://pubmed.ncbi.nlm.nih.gov/36720133).\",\"url\":\"http://www.nejm.org/doi/10.1056/NEJMoa2209226\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Malec, Lynn; Peyvandi, Flora; Chan, Anthony K.C.; KÃ¶nigs, Christoph; Zulfikar, Bulent; Yuan, Huixing; Simpson, Mindy; Ãlvarez RomÃ¡n, Maria Teresa; Carcao, Manuel; Staber, Janice M.; Dunn, Amy L.; Chou, Sheng-Chieh; d'Oiron, Roseline; Albisetti, Manuela; Demissie, Marek (2024-07-18). [\\\"Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A\\\"](http://www.nejm.org/doi/10.1056/NEJMoa2312611). _New England Journal of Medicine_. **391** (3): 235â€“246\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa2312611](https://doi.org/10.1056%2FNEJMoa2312611). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [39018533](https://pubmed.ncbi.nlm.nih.gov/39018533).\",\"description\":\"16. **^** Malec, Lynn; Peyvandi, Flora; Chan, Anthony K.C.; KÃ¶nigs, Christoph; Zulfikar, Bulent; Yuan, Huixing; Simpson, Mindy; Ãlvarez RomÃ¡n, Maria Teresa; Carcao, Manuel; Staber, Janice M.; Dunn, Amy L.; Chou, Sheng-Chieh; d'Oiron, Roseline; Albisetti, Manuela; Demissie, Marek (2024-07-18). [\\\"Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A\\\"](http://www.nejm.org/doi/10.1056/NEJMoa2312611). _New England Journal of Medicine_. **391** (3): 235â€“246\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa2312611](https://doi.org/10.1056%2FNEJMoa2312611). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [39018533](https://pubmed.ncbi.nlm.nih.gov/39018533).\",\"url\":\"http://www.nejm.org/doi/10.1056/NEJMoa2312611\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Ma, Alice D.; Roberts, Harold R.; Escobar, Miguel A. (2012-10-03). [_Hemophilia and Hemostasis: A Case-Based Approach to Management_](https://books.google.com/books?id=JeCD7cUVeTEC). John Wiley \u0026 Sons. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781118439302.Google books no page\",\"description\":\"17. **^** Ma, Alice D.; Roberts, Harold R.; Escobar, Miguel A. (2012-10-03). [_Hemophilia and Hemostasis: A Case-Based Approach to Management_](https://books.google.com/books?id=JeCD7cUVeTEC). John Wiley \u0026 Sons. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781118439302.Google books no page\",\"url\":\"https://books.google.com/books?id=JeCD7cUVeTEC\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Santagostino, Elena; Mancuso, Maria Elisa (2008-09-01). [\\\"Barriers to primary prophylaxis in haemophilic children: the issue of the venous access\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652218). _Blood Transfusion_. **6** (Suppl 2): s12 â€“ s16. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2450/2008.0031-08](https://doi.org/10.2450%2F2008.0031-08). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1723-2007](https://search.worldcat.org/issn/1723-2007). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2652218](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652218). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19105504](https://pubmed.ncbi.nlm.nih.gov/19105504).\",\"description\":\"18. **^** Santagostino, Elena; Mancuso, Maria Elisa (2008-09-01). [\\\"Barriers to primary prophylaxis in haemophilic children: the issue of the venous access\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652218). _Blood Transfusion_. **6** (Suppl 2): s12 â€“ s16. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2450/2008.0031-08](https://doi.org/10.2450%2F2008.0031-08). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1723-2007](https://search.worldcat.org/issn/1723-2007). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2652218](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652218). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19105504](https://pubmed.ncbi.nlm.nih.gov/19105504).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652218\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** [\\\"Guidelines for the Prevention of Intravascular Catheter-Related Infections\\\"](https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm). _www.cdc.gov_. Retrieved 8 July 2016.\",\"description\":\"19. **^** [\\\"Guidelines for the Prevention of Intravascular Catheter-Related Infections\\\"](https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm). _www.cdc.gov_. Retrieved 8 July 2016.\",\"url\":\"https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** Ljung, Rolf (2007-09-01). [\\\"The risk associated with indwelling catheters in children with haemophilia\\\"](https://doi.org/10.1111%2Fj.1365-2141.2007.06703.x). _British Journal of Haematology_. **138** (5): 580â€“586\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1365-2141.2007.06703.x](https://doi.org/10.1111%2Fj.1365-2141.2007.06703.x). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1365-2141](https://search.worldcat.org/issn/1365-2141). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17686052](https://pubmed.ncbi.nlm.nih.gov/17686052). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25748135](https://api.semanticscholar.org/CorpusID:25748135).\",\"description\":\"20. **^** Ljung, Rolf (2007-09-01). [\\\"The risk associated with indwelling catheters in children with haemophilia\\\"](https://doi.org/10.1111%2Fj.1365-2141.2007.06703.x). _British Journal of Haematology_. **138** (5): 580â€“586\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1365-2141.2007.06703.x](https://doi.org/10.1111%2Fj.1365-2141.2007.06703.x). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1365-2141](https://search.worldcat.org/issn/1365-2141). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17686052](https://pubmed.ncbi.nlm.nih.gov/17686052). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25748135](https://api.semanticscholar.org/CorpusID:25748135).\",\"url\":\"https://doi.org/10.1111%2Fj.1365-2141.2007.06703.x\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Franchini, Massimo; Lippi, Giuseppe (2011-10-01). [\\\"The use of desmopressin in acquired haemophilia A: a systematic review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200405). _Blood Transfusion_. **9** (4): 377â€“382\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2450/2011.0113-10](https://doi.org/10.2450%2F2011.0113-10). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1723-2007](https://search.worldcat.org/issn/1723-2007). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3200405](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200405). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21839010](https://pubmed.ncbi.nlm.nih.gov/21839010).\",\"description\":\"21. **^** Franchini, Massimo; Lippi, Giuseppe (2011-10-01). [\\\"The use of desmopressin in acquired haemophilia A: a systematic review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200405). _Blood Transfusion_. **9** (4): 377â€“382\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2450/2011.0113-10](https://doi.org/10.2450%2F2011.0113-10). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1723-2007](https://search.worldcat.org/issn/1723-2007). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3200405](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200405). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21839010](https://pubmed.ncbi.nlm.nih.gov/21839010).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200405\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** [\\\"FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors\\\"](https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors). _U.S. Food and Drug Administration_. 28 March 2025. Retrieved 29 March 2025.\",\"description\":\"22. **^** [\\\"FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors\\\"](https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors). _U.S. Food and Drug Administration_. 28 March 2025. Retrieved 29 March 2025.\",\"url\":\"https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** [\\\"Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors\\\"](https://www.news.sanofi.us/2025-03-28-Qfitlia-approved-as-the-first-therapy-in-the-US-to-treat-hemophilia-A-or-B-with-or-without-inhibitors). _Sanofi_ (Press release). 28 March 2025. Retrieved 29 March 2025.\",\"description\":\"23. **^** [\\\"Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors\\\"](https://www.news.sanofi.us/2025-03-28-Qfitlia-approved-as-the-first-therapy-in-the-US-to-treat-hemophilia-A-or-B-with-or-without-inhibitors). _Sanofi_ (Press release). 28 March 2025. Retrieved 29 March 2025.\",\"url\":\"https://www.news.sanofi.us/2025-03-28-Qfitlia-approved-as-the-first-therapy-in-the-US-to-treat-hemophilia-A-or-B-with-or-without-inhibitors\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** _Andrew Brewer, Maria Elvira Correa (May 2006). \\\"Guildelines for Dental Treatment of Patients with Inherited Bleeding Disorders\\\" (PDF). Treatment of Hemophilia.**40** : 9 â€“ via World Federation of Hemophilia (WFH)._\",\"description\":\"24. **^** _Andrew Brewer, Maria Elvira Correa (May 2006). \\\"Guildelines for Dental Treatment of Patients with Inherited Bleeding Disorders\\\" (PDF). Treatment of Hemophilia.**40** : 9 â€“ via World Federation of Hemophilia (WFH)._\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** [\\\"Groundbreaking gene therapy trial set to cure haemophilia A\\\"](https://www.bartshealth.nhs.uk/news/groundbreaking-gene-therapy-trial-set-to-cure-haemophilia-a-2529). _Barts Health NHS Trust_. 14 December 2017. Retrieved 14 December 2017.\",\"description\":\"25. **^** [\\\"Groundbreaking gene therapy trial set to cure haemophilia A\\\"](https://www.bartshealth.nhs.uk/news/groundbreaking-gene-therapy-trial-set-to-cure-haemophilia-a-2529). _Barts Health NHS Trust_. 14 December 2017. Retrieved 14 December 2017.\",\"url\":\"https://www.bartshealth.nhs.uk/news/groundbreaking-gene-therapy-trial-set-to-cure-haemophilia-a-2529\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** [\\\"Haemophilia A trial results 'mind-blowing'\\\"](https://www.bbc.com/news/health-42337396). _BBC_. 14 December 2017. Retrieved 14 December 2017.\",\"description\":\"26. **^** [\\\"Haemophilia A trial results 'mind-blowing'\\\"](https://www.bbc.com/news/health-42337396). _BBC_. 14 December 2017. Retrieved 14 December 2017.\",\"url\":\"https://www.bbc.com/news/health-42337396\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Rangarajan, Savita; Walsh, Liron; Lester, Will; Perry, David; Madan, Bella; Laffan, Michael; Yu, Hua; Vettermann, Christian; Pierce, Glenn F.; Wong, Wing Y.; Pasi, K. John (16 December 2017). [\\\"AAV5â€“Factor VIII Gene Transfer in Severe Hemophilia A\\\"](http://qmro.qmul.ac.uk/xmlui/handle/123456789/31880). _New England Journal of Medicine_. **377** (26): 2519â€“2530\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa1708483](https://doi.org/10.1056%2FNEJMoa1708483). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10044/1/57163](https://hdl.handle.net/10044%2F1%2F57163). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29224506](https://pubmed.ncbi.nlm.nih.gov/29224506).\",\"description\":\"27. **^** Rangarajan, Savita; Walsh, Liron; Lester, Will; Perry, David; Madan, Bella; Laffan, Michael; Yu, Hua; Vettermann, Christian; Pierce, Glenn F.; Wong, Wing Y.; Pasi, K. John (16 December 2017). [\\\"AAV5â€“Factor VIII Gene Transfer in Severe Hemophilia A\\\"](http://qmro.qmul.ac.uk/xmlui/handle/123456789/31880). _New England Journal of Medicine_. **377** (26): 2519â€“2530\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa1708483](https://doi.org/10.1056%2FNEJMoa1708483). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10044/1/57163](https://hdl.handle.net/10044%2F1%2F57163). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29224506](https://pubmed.ncbi.nlm.nih.gov/29224506).\",\"url\":\"http://qmro.qmul.ac.uk/xmlui/handle/123456789/31880\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** Marchesini, Emanuela; Morfini, Massimo; Valentino, Leonard (2021-06-15). [\\\"Recent Advances in the Treatment of Hemophilia: A Review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214539). _Biologics: Targets and Therapy_. **15** : 221â€“235\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2147/BTT.S252580](https://doi.org/10.2147%2FBTT.S252580). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8214539](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214539). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34163136](https://pubmed.ncbi.nlm.nih.gov/34163136).\",\"description\":\"28. **^** Marchesini, Emanuela; Morfini, Massimo; Valentino, Leonard (2021-06-15). [\\\"Recent Advances in the Treatment of Hemophilia: A Review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214539). _Biologics: Targets and Therapy_. **15** : 221â€“235\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2147/BTT.S252580](https://doi.org/10.2147%2FBTT.S252580). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8214539](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214539). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34163136](https://pubmed.ncbi.nlm.nih.gov/34163136).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214539\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Milani, Michela; Canepari, Cesare; Assanelli, Simone; Merlin, Simone; Borroni, Ester; Starinieri, Francesco; Biffi, Mauro; Russo, Fabio; Fabiano, Anna; Zambroni, DesirÃ¨e; Annoni, Andrea; Naldini, Luigi; Follenzi, Antonia; Cantore, Alessio (2024-04-29). [\\\"GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178766). _EMBO Molecular Medicine_. **16** (6): 1427â€“1450\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s44321-024-00072-8](https://doi.org/10.1038%2Fs44321-024-00072-8). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1757-4684](https://search.worldcat.org/issn/1757-4684). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [11178766](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178766). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [38684862](https://pubmed.ncbi.nlm.nih.gov/38684862).\",\"description\":\"29. **^** Milani, Michela; Canepari, Cesare; Assanelli, Simone; Merlin, Simone; Borroni, Ester; Starinieri, Francesco; Biffi, Mauro; Russo, Fabio; Fabiano, Anna; Zambroni, DesirÃ¨e; Annoni, Andrea; Naldini, Luigi; Follenzi, Antonia; Cantore, Alessio (2024-04-29). [\\\"GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178766). _EMBO Molecular Medicine_. **16** (6): 1427â€“1450\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s44321-024-00072-8](https://doi.org/10.1038%2Fs44321-024-00072-8). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1757-4684](https://search.worldcat.org/issn/1757-4684). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [11178766](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178766). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [38684862](https://pubmed.ncbi.nlm.nih.gov/38684862).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178766\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** [\\\"Hemlibra (emicizumab-kxwh) Injection\\\"](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761083Orig1s000TOC.cfm). _accessdata.fda.gov_. 29 December 2017. Retrieved 29 March 2025.\",\"description\":\"30. **^** [\\\"Hemlibra (emicizumab-kxwh) Injection\\\"](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761083Orig1s000TOC.cfm). _accessdata.fda.gov_. 29 December 2017. Retrieved 29 March 2025.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761083Orig1s000TOC.cfm\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"** Malec, Lynn; Peyvandi, Flora; Chan, Anthony K.C.; KÃ¶nigs, Christoph; Zulfikar, Bulent; Yuan, Huixing; Simpson, Mindy; Ãlvarez RomÃ¡n, Maria Teresa; Carcao, Manuel; Staber, Janice M.; Dunn, Amy L.; Chou, Sheng-Chieh; d'Oiron, Roseline; Albisetti, Manuela; Demissie, Marek (2024-07-18). [\\\"Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A\\\"](http://www.nejm.org/doi/10.1056/NEJMoa2312611). _New England Journal of Medicine_. **391** (3): 235â€“246\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa2312611](https://doi.org/10.1056%2FNEJMoa2312611). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [39018533](https://pubmed.ncbi.nlm.nih.gov/39018533).\",\"description\":\"31. **^** Malec, Lynn; Peyvandi, Flora; Chan, Anthony K.C.; KÃ¶nigs, Christoph; Zulfikar, Bulent; Yuan, Huixing; Simpson, Mindy; Ãlvarez RomÃ¡n, Maria Teresa; Carcao, Manuel; Staber, Janice M.; Dunn, Amy L.; Chou, Sheng-Chieh; d'Oiron, Roseline; Albisetti, Manuela; Demissie, Marek (2024-07-18). [\\\"Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A\\\"](http://www.nejm.org/doi/10.1056/NEJMoa2312611). _New England Journal of Medicine_. **391** (3): 235â€“246\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa2312611](https://doi.org/10.1056%2FNEJMoa2312611). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [39018533](https://pubmed.ncbi.nlm.nih.gov/39018533).\",\"url\":\"http://www.nejm.org/doi/10.1056/NEJMoa2312611\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** Chowdary, Pratima (2024-07-18). Phimister, Elizabeth G. (ed.). [\\\"Bioengineered Factor VIII â€” More Innovation for Hemophilia A\\\"](http://www.nejm.org/doi/10.1056/NEJMe2313795). _New England Journal of Medicine_. **391** (3): 277â€“282\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMe2313795](https://doi.org/10.1056%2FNEJMe2313795). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [39018538](https://pubmed.ncbi.nlm.nih.gov/39018538).\",\"description\":\"32. **^** Chowdary, Pratima (2024-07-18). Phimister, Elizabeth G. (ed.). [\\\"Bioengineered Factor VIII â€” More Innovation for Hemophilia A\\\"](http://www.nejm.org/doi/10.1056/NEJMe2313795). _New England Journal of Medicine_. **391** (3): 277â€“282\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMe2313795](https://doi.org/10.1056%2FNEJMe2313795). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [39018538](https://pubmed.ncbi.nlm.nih.gov/39018538).\",\"url\":\"http://www.nejm.org/doi/10.1056/NEJMe2313795\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Triemstra, Mattanja (1995-12-01). \\\"Mortality in Patients with Hemophilia: Changes in a Dutch Population from 1986 to 1992 and 1973 to 1986\\\". _Annals of Internal Medicine_. **123** (11): 823â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7326/0003-4819-123-11-199512010-00002](https://doi.org/10.7326%2F0003-4819-123-11-199512010-00002). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0003-4819](https://search.worldcat.org/issn/0003-4819). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7486463](https://pubmed.ncbi.nlm.nih.gov/7486463). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [22008880](https://api.semanticscholar.org/CorpusID:22008880).\",\"description\":\"33. **^** Triemstra, Mattanja (1995-12-01). \\\"Mortality in Patients with Hemophilia: Changes in a Dutch Population from 1986 to 1992 and 1973 to 1986\\\". _Annals of Internal Medicine_. **123** (11): 823â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7326/0003-4819-123-11-199512010-00002](https://doi.org/10.7326%2F0003-4819-123-11-199512010-00002). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0003-4819](https://search.worldcat.org/issn/0003-4819). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7486463](https://pubmed.ncbi.nlm.nih.gov/7486463). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [22008880](https://api.semanticscholar.org/CorpusID:22008880).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"_**a**_ _**b**_ Plug, I.; Van Der Bom, J. G.; Peters, M.; Mauser-Bunschoten, E. P.; De Goede-Bolder, A.; Heijnen, L.; Smit, C.; Willemse, J.; Rosendaal, F. R. (2006-03-01). \\\"Mortality and causes of death in patients with hemophilia, 1992â€“2001: a prospective cohort study1\\\". _Journal of Thrombosis and Haemostasis_. **4** (3): 510â€“516\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1538-7836.2006.01808.x](https://doi.org/10.1111%2Fj.1538-7836.2006.01808.x). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[1887/5021](https://hdl.handle.net/1887%2F5021). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1538-7836](https://search.worldcat.org/issn/1538-7836). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16460432](https://pubmed.ncbi.nlm.nih.gov/16460432). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [13651790](https://api.semanticscholar.org/CorpusID:13651790).\",\"description\":\"34. ^ _**a**_ _**b**_ Plug, I.; Van Der Bom, J. G.; Peters, M.; Mauser-Bunschoten, E. P.; De Goede-Bolder, A.; Heijnen, L.; Smit, C.; Willemse, J.; Rosendaal, F. R. (2006-03-01). \\\"Mortality and causes of death in patients with hemophilia, 1992â€“2001: a prospective cohort study1\\\". _Journal of Thrombosis and Haemostasis_. **4** (3): 510â€“516\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1538-7836.2006.01808.x](https://doi.org/10.1111%2Fj.1538-7836.2006.01808.x). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[1887/5021](https://hdl.handle.net/1887%2F5021). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1538-7836](https://search.worldcat.org/issn/1538-7836). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16460432](https://pubmed.ncbi.nlm.nih.gov/16460432). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [13651790](https://api.semanticscholar.org/CorpusID:13651790).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Bleeding time,[2] coagulation screen, genetic testing\",\"explanation\":\"The cited source [2] (MedlinePlus) does not mention bleeding time as a diagnostic method for hemophilia A. Bleeding time assesses platelet function and is typically normal in hemophilia A, which affects coagulation factors. Standard diagnostics include activated partial thromboplastin time (aPTT), factor VIII activity assay, and genetic testing.\",\"fixedText\":\"Replace \\\"Bleeding time\\\" with \\\"Activated partial thromboplastin time (aPTT)\\\" and retain the other methods with appropriate citation.\",\"evidenceSource\":\"[2]\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"Factor VIII, factor VIII inhibitors, emicizumab\",\"explanation\":\"\\\"Factor VIII inhibitors\\\" refers to neutralizing antibodies against factor VIII, which are a complication of treatment, not a therapeutic agent. This misrepresents the treatment options. Correct treatments include factor VIII replacement, bypassing agents (e.g., recombinant factor VIIa or activated prothrombin complex) for patients with inhibitors, and non-factor therapies like emicizumab.\",\"fixedText\":\"Revise to \\\"Factor VIII replacement, bypassing agents for inhibitors, emicizumab\\\" and add citation for emicizumab.\",\"evidenceSource\":\"[6] [30]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention\",\"explanation\":\"The introduction lacks reference to key modern treatment advancements as of 2025, such as prophylactic regimens (standard for severe cases), subcutaneous non-factor therapies beyond emicizumab (e.g., efanesoctocog alfa), and approved gene therapies (e.g., Roctavian since 2023). This creates a knowledge gap on current management, especially given the article's recency and separate Treatment section.\",\"fixedText\":\"Add a concise overview in the management paragraph: \\\"Treatment primarily involves prophylactic replacement of factor VIII via intravenous infusion, non-factor prophylactic therapies like emicizumab (subcutaneous), and emerging options such as gene therapy (approved as of 2023).\\\"\",\"evidenceSource\":\"[](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia) [](https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"The Complications subsection discusses only inhibitor development and its treatment, without mentioning major disease-related complications.\",\"explanation\":\"Haemophilia A has well-established primary complications such as recurrent hemarthrosis leading to chronic joint disease (hemophilic arthropathy), which is the leading cause of morbidity and disability, as well as risks like intracranial hemorrhage. Omitting these creates an incomplete and misleading portrayal of the condition's impact, potentially affecting reader understanding of long-term risks.\",\"fixedText\":\"Add details on key complications including hemophilic arthropathy from repeated joint bleeds and intracranial hemorrhage as a life-threatening risk, citing [1].\",\"evidenceSource\":\"[1]; https://www.ncbi.nlm.nih.gov/books/NBK1404/\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"levels of factor VIII and [IX](Factor_IX \\\"Factor IX\\\") be measured in all known or potential carriers prior to surgery and in the event of clinically significant bleeding.\",\"explanation\":\"Factor IX is associated with hemophilia B, not hemophilia A. Recommendations for carriers of hemophilia A involve measuring factor VIII levels only to assess bleeding risk, not factor IX.\",\"fixedText\":\"Remove mention of factor IX: change to \\\"levels of factor VIII be measured in all known or potential carriers prior to surgery and in the event of clinically significant bleeding.\\\"\",\"evidenceSource\":\"Ref [1]; WFH Guidelines for the Management of Hemophilia [](https://www1.wfh.org/publications/files/pdf-1863.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"Since both forms of haemophilia can be caused by a variety of different mutations\",\"explanation\":\"This section concerns only hemophilia A; referencing \\\"both forms\\\" (implying hemophilia A and B) introduces irrelevant scope from the separate hemophilia B article and misstates applicability.\",\"fixedText\":\"Change to \\\"Since haemophilia A can be caused by a variety of different mutations\\\"\",\"evidenceSource\":\"Article structure (separate sections/articles for A and B); page title Haemophilia A\"},{\"criticality\":\"Missing Information\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific mention of the causative gene name or chromosomal location.]\",\"explanation\":\"The genetics section lacks the standard factual detail of the specific gene (F8) and its location (Xq28), which is essential for completeness and understanding the molecular basis.\",\"fixedText\":\"Add at the beginning of the section: \\\"Haemophilia A is caused by pathogenic variants in the F8 gene, which encodes coagulation factor VIII and is located on the long arm of the X chromosome (Xq28).\\\"\",\"evidenceSource\":\"Ref [1] [](https://www.ncbi.nlm.nih.gov/books/NBK1404/); Ref [12] [](http://omim.org/entry/306700)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Recently, genetic testing has been made available to determine an individual's risk of attaining or passing on haemophilia.\\\"\",\"explanation\":\"Genetic testing for hemophilia A has been available since the 1990s and is now a standard part of diagnosis and counseling, not \\\"recently\\\" as of 2025. This outdated phrasing misrepresents current medical practice.\",\"fixedText\":\"Replace with: \\\"Genetic testing is available to determine an individual's risk of inheriting or passing on haemophilia.\\\"\",\"evidenceSource\":\"WFH Guidelines 3rd edition (2020)[](https://www1.wfh.org/publications/files/pdf-1863.pdf); Patient.info [3]\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"an increased partial thromboplastin time (PTT) in the context of a normal prothrombin time (PT) and bleeding time.\\\"\",\"explanation\":\"The bleeding time test is obsolete and not recommended in current guidelines for diagnosing hemophilia A, as it assesses primary hemostasis (normal in hemophilia) but has been replaced by more accurate tests like PFA-100. Including it misstates standard diagnostic procedures and could confuse clinical practice.\",\"fixedText\":\"Remove mention of bleeding time: \\\"an increased partial thromboplastin time (PTT) in the context of a normal prothrombin time (PT).\\\"\",\"evidenceSource\":\"WFH Guidelines 3rd edition (2020)[](https://www1.wfh.org/publications/files/pdf-1863.pdf); CDC Diagnosis Guidelines (2024)[](https://www.cdc.gov/hemophilia/testing/index.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"PTT tests are the first blood test done when haemophilia is indicated.[12]\\\"\",\"explanation\":\"While OMIM [12] mentions prolonged PTT, current guidelines specify screening with both PT and APTT (PTT), not PTT alone as the first test. This overstates PTT's role and mismatches modern protocols.\",\"fixedText\":\"Revise to: \\\"Screening tests, including activated partial thromboplastin time (APTT or PTT) and prothrombin time (PT), are performed when hemophilia is suspected.\\\"\",\"evidenceSource\":\"WFH Guidelines 3rd edition (2020)[](https://www1.wfh.org/publications/files/pdf-1863.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention.\",\"explanation\":\"The section lacks detail on prenatal and carrier testing, which are key aspects of diagnosis per current guidelines, especially since genetic testing is discussed. This creates a knowledge gap in comprehensive diagnostic approaches.\",\"fixedText\":\"Add: \\\"Genetic testing also enables carrier detection in females and prenatal diagnosis, often using techniques such as next-generation sequencing (NGS) for F8 gene mutations.\\\"\",\"evidenceSource\":\"WFH Guidelines 3rd edition (2020)[](https://www1.wfh.org/publications/files/pdf-1863.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Some individuals with severe haemophilia, and most with moderate and mild haemophilia, treat only as needed without a regular prophylactic schedule.[20]\",\"explanation\":\"Reference 20 discusses risks associated with indwelling catheters in children with haemophilia but does not address treatment schedules or prophylaxis versus on-demand treatment for different severities of haemophilia A.\",\"fixedText\":\"Replace citation [20] with [1], as GeneReviews (ref 1) supports that prophylaxis is standard for severe haemophilia A, while on-demand is typical for moderate and mild unless frequent bleeding occurs.\",\"evidenceSource\":\"Ref 20\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Mild haemophiliacs often manage their condition with desmopressin, a drug which releases stored factor VIII from blood vessel walls.[21]\",\"explanation\":\"Reference 21 focuses on the use of desmopressin in acquired haemophilia A, not in congenital mild haemophilia A.\",\"fixedText\":\"Replace citation [21] with [1], as GeneReviews (ref 1) confirms desmopressin is effective for mild haemophilia A by increasing factor VIII levels.\",\"evidenceSource\":\"Ref 21\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"A study published in July 2024, demonstrated that efanesoctocog alfa, a bioengineered human factor VIII recombinant protein, prophylaxis for children with severe hemophilia A could have therapeutic benefit leading to effective bleeding prevention.[31][32]\",\"explanation\":\"This paragraph is placed under the \\\"Monoclonal antibodies\\\" subsection, but efanesoctocog alfa is a recombinant factor VIII fusion protein, not a monoclonal antibody. It duplicates information already in the main section.\",\"fixedText\":\"Remove this paragraph from the \\\"Monoclonal antibodies\\\" subsection to avoid misclassification and duplication; the information is already covered in the main treatment text with citations [15][16].\",\"evidenceSource\":\"Ref 15, 16, 31, 32\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"In December 2017, it was reported that doctors had used a new form of gene therapy to treat haemophilia A.[25][26][27] Current treatment efforts utilize adeno-associated virus (AAV) vectors, however recent studies have found lentiviral vectors (LV) as being a more effective alternative. [28][29]\",\"explanation\":\"The section references a 2017 trial but fails to mention that AAV-based gene therapy (valoctocogene roxaparvovec, Roctavian) was approved by the FDA in 2023 for adults with severe haemophilia A without inhibitors, making it a current approved treatment as of 2025. Lentiviral vectors are limited to preclinical studies (e.g., mouse models in ref 29) and not established as a clinical alternative.\",\"fixedText\":\"Update the subsection to include the 2023 FDA approval of valoctocogene roxaparvovec for adults with severe haemophilia A; qualify lentiviral vectors as promising in preclinical research rather than a current alternative. Add citation for approval: [](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products).\",\"evidenceSource\":\"Ref 25-29; FDA approval announcement\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire Gene therapy subsection]\",\"explanation\":\"The subsection lacks details on approved gene therapies available as of 2025, such as valoctocogene roxaparvovec (Roctavian), approved in 2023 for adults with severe haemophilia A (FVIII \u003c1 IU/dL) without AAV5 antibodies or inhibitors. This omission affects the currency and completeness of treatment options.\",\"fixedText\":\"Add information on approved gene therapy: Valoctocogene roxaparvovec (Roctavian) was approved by the FDA in June 2023 for adults with severe haemophilia A without preexisting inhibitors. It uses an AAV5 vector to deliver a modified F8 gene, enabling endogenous FVIII production.\",\"evidenceSource\":\"FDA approval data\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"In the latest study which followed patients from 1992 to 2001, the male life expectancy was 59 years. If cases with known viral infections were excluded, the life expectancy was 72, close to that of the general population. 26% of the cases died from AIDS and 22% from hepatitis C.[34]\",\"explanation\":\"These statistics are from a study ending in 2001, over 20 years ago. Since then, life expectancy for hemophilia A has improved significantly due to better infection control, prophylaxis, and new treatments like gene therapy, approaching normal levels in high-income countries (median ~73-77 years for severe cases). Presenting outdated data without sufficient recent context misrepresents current prognosis, potentially affecting patient expectations or clinical understanding.\",\"fixedText\":\"Update with recent data: e.g., A 2022 Dutch study (2001-2018) reported median life expectancy of 73 years for severe hemophilia A, 6 years below the general population. Causes of death have shifted to malignancies and intracranial bleeding.\",\"evidenceSource\":\"[](https://www.sciencedirect.com/science/article/pii/S1538783622006766)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"However, these statistics for prognosis are unreliable as there has been marked improvement of [infection control](Infection_control \\\"Infection control\\\") and efficacy of [anti-retroviral drugs](Anti-retroviral_drugs \\\"Anti-retroviral drugs\\\") since these studies were done.\",\"explanation\":\"The cited studies [33][34] support the historical data but do not address post-2001 improvements comprehensively. Recent literature shows broader advancements (e.g., factor prophylaxis, non-factor therapies) have further normalized life expectancy, making the section's reliance on old refs incomplete for current prognosis.\",\"fixedText\":\"Retain acknowledgment of improvements but expand with sourced recent data on life expectancy and causes of death to match current evidence.\",\"evidenceSource\":\"[](https://www.sciencedirect.com/science/article/pii/S1538783622021274)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific quote; entire section lacks recent data]\",\"explanation\":\"The section omits key recent developments: life expectancy now nears general population in treated patients (e.g., median 77 years overall in Netherlands 2001-2018); causes of death shifted from infections (HIV/HCV now rare) to cardiovascular disease, malignancies, and bleeding. This gap leaves the prognosis outdated as of 2025.\",\"fixedText\":\"Add: In high-income countries with access to modern care, life expectancy for severe hemophilia A is approximately 70-77 years, within 5-10 years of the general male population. Primary causes of death include malignancies (26%), intracranial hemorrhage (14%), and cardiovascular events.\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7086468/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"The entire section is brief and lacks details on prevalence, global distribution, and underdiagnosis.\",\"explanation\":\"Epidemiology sections typically include both incidence and prevalence, regional variations, and challenges like underreporting in developing countries, which affect understanding of the disease burden. Recent WFH data estimates higher global numbers due to improved reporting and undiagnosed cases.\",\"fixedText\":\"Add global prevalence estimates (e.g., ~1 in 5,000 male births for incidence of A; prevalence ~13 per 100,000 males globally as per recent studies), note ~400,000-800,000 affected worldwide with many undiagnosed, especially in low-income regions.\",\"evidenceSource\":\"[](https://wfh.org/) World Federation of Hemophilia reports; [](https://www.cdc.gov/hemophilia/data-research/index.html) CDC data\"},{\"criticality\":\"Non-Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Citation [10] from 2011\",\"explanation\":\"While numbers remain standard, updating with recent sources (e.g., 2024 CDC/WFH) would improve currency, but does not alter the approximate values significantly.\",\"fixedText\":\"Retain but supplement with new citations for recent data.\",\"evidenceSource\":\"[10]; recent searches\"}],\"slug\":\"Haemophilia_A\",\"title\":\"Haemophilia A\",\"content\":\"$1f\",\"description\":\"Haemophilia A\\n\\n| Attribute | Details |\\n|---------------|-------------|\\n| Other names | Hemophilia A |\\n| Specialty | Haematology |\\n| Symptoms | Prolonged bleeding from common injuries[1] |\\n| Causes |...\",\"metadata\":{\"categories\":[\"Hemophilia A\",\"Classic hemophilia\",\"Classical hemophilia\",\"Factor VIII deficiency\"],\"lastModified\":\"1761553913\",\"contentLength\":\"13989\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"35156\",\"recentViews\":\"35156\",\"dailyAvgViews\":1171.86669921875,\"qualityScore\":1,\"lastViewed\":\"1761887609\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761887609733,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Haemophilia_A\"],\"queryHash\":\"[\\\"page\\\",\\\"Haemophilia_A\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Haemophilia A\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Haemophilia A (or hemophilia A) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.[2][3][4] The medical management of individuals with hemophilia A primarily involves...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Hemophilia A, Classic hemophilia, Classical hemophilia, Factor VIII deficiency\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Haemophilia_A\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Haemophilia A\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Haemophilia A (or hemophilia A) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.[2][3][4] The medical management of individuals with hemophilia A primarily involves...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Haemophilia_A\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Haemophilia A\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.913Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Haemophilia A\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Haemophilia A (or hemophilia A) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.[2][3][4] The medical management of individuals with hemophilia A primarily involves...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YzFkMTk4N2YtZjVlNi00YWQ0LWJjMjctNzE4YmJmZjM5OThm">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Haemophilia_A\"}]}]\n"])</script></body></html>